CagriSema: Trial Results, FDA Status, Side Effects, and Availability

13 min read

Share

A pale sky blue felt medication vial with a navy crimped cap.

TL;DR

There is no confirmed CagriSema launch date in the United States as of October 20, 2026. CagriSema remains an investigational once-weekly injection that combines cagrilintide and semaglutide. The supplied sources do not establish FDA approval, a US launch date, a US price, or insurance coverage.

The American Diabetes Association reported weight loss of up to 22.7% in studied adults without diabetes and 15.7% in those with type 2 diabetes. These trial results depend on the population and analysis used. They do not predict individual outcomes.

What is CagriSema?

What is CagriSema?

CagriSema is an investigational combination of cagrilintide and semaglutide, administered in trials as a once-weekly injection.

Source status checked October 20, 2026

  • FDA approval established: No
  • Confirmed US launch date: None
  • Confirmed US price: None
  • Confirmed insurance coverage: None

Cagrilintide is an amylin receptor agonist. Semaglutide is a GLP-1 receptor agonist. CagriSema therefore contains a GLP-1 medicine, but it is not another name for semaglutide.

Is CagriSema a GLP-1 drug?

Partly. Semaglutide targets GLP-1 receptors, while cagrilintide acts through the amylin pathway. Calling CagriSema simply “a GLP-1” omits one of its two active ingredients.

How do cagrilintide and semaglutide work together?

The combination is being studied for its effects on appetite, food intake, body weight, and glucose regulation. A proposed mechanism cannot predict an individual result or prove superiority over an approved treatment.

What injection device will CagriSema use?

The reviewed trial material confirms a once-weekly injection. It does not confirm the final commercial device. It does not establish whether the approved product, if approved, will use a prefilled pen, vial, or another device.

A trial injection method and a future commercial device are separate questions. The manufacturer and regulator must confirm the final device.

CagriSema weight-loss trial results: what the numbers measure

Trial percentages require context. We look at the patient group, treatment period, dose, comparator, discontinuations, and statistical method before drawing conclusions.

StudyPopulationReported finding
REDEFINE 1Adults with overweight or obesity without diabetesWeight loss of up to 22.7%
REDEFINE 2Adults with excess weight and type 2 diabetesWeight loss of up to 15.7%
REIMAGINE 1Adults with type 2 diabetes inadequately controlled by diet and exerciseStudied glucose control and body-weight outcomes

The ADA figures are study-level findings, not promised results. An analysis that assumes participants remain on treatment may answer a different question from one that accounts for treatment discontinuation and missing observations.

REDEFINE 1 results in adults with obesity or overweight

REDEFINE 1 studied CagriSema in adults without diabetes. The American Diabetes Association reported weight loss of up to 22.7%.

That figure should remain tied to the study population and reported analysis. We recommend checking the full peer-reviewed publication before comparing detailed completion, discontinuation, or treatment-arm results.

REDEFINE 2 results in adults with type 2 diabetes

REDEFINE 2 studied adults with type 2 diabetes and excess body weight. The ADA reported weight loss of up to 15.7%.

Results in people with type 2 diabetes should not be treated as forecasts for people without diabetes. Enrollment criteria, health conditions, background treatment, and treatment response can differ.

What does “up to” mean in these results?

“Up to” does not mean that every participant lost that amount of weight. It refers to a reported study result under a stated analysis. The result may depend on the treatment group, follow-up period, dose, and handling of participants who stopped treatment.

The CagriSema Phase 3 trial program

The CagriSema Phase 3 trial program

Different CagriSema trials answer different clinical questions.

StudyPopulation and focus
REDEFINE 1Weight management in adults without diabetes
REDEFINE 2Weight management in adults with type 2 diabetes
REIMAGINE 1Glucose control in adults with type 2 diabetes inadequately controlled by diet and exercise

Phase 3 findings do not create an approved indication. Regulatory authorities must review the complete evidence before approving a product and its label.

REDEFINE trials for weight management

REDEFINE trials examine weight-related outcomes in defined populations. Their endpoints, comparators, dose plans, and approaches to missing data may differ, so we do not treat their results as interchangeable.

REIMAGINE trials for type 2 diabetes

REIMAGINE studies focus on type 2 diabetes. REIMAGINE 1 was a randomized, double-blind Phase 3a study conducted at 42 sites in six countries. It compared two CagriSema dose levels with matching placebo over 40 weeks.

What were the CagriSema Phase 3 results in 2026?

The reviewed 2026 material includes results from the Phase 3 program, including the reported REDEFINE findings and the REIMAGINE 1 publication. The reported weight-loss figures were up to 22.7% in studied adults without diabetes and 15.7% in studied adults with type 2 diabetes.

Those results do not establish FDA approval. They also do not provide a confirmed 2026 launch date, final label, final device, price, or insurance benefit.

Has CagriSema been submitted to the FDA?

The reviewed sources do not establish a confirmed FDA submission date or a publicly verified CagriSema application number. A trial registry entry, conference result, or company development update is not the same as proof that the FDA has accepted a marketing application.

For the current US status, check the FDA’s official drug databases and the manufacturer’s current regulatory statements. A reliable status update should identify the product, the application or filing, and the relevant date.

What source confirms CagriSema’s regulatory status in the United States?

The FDA is the relevant US source for approval status. The clinical-trial records linked above show that CagriSema is being studied. They do not confirm approval or a launch date.

As of October 20, 2026, the supplied sources do not provide an FDA approval record for CagriSema. They also do not provide a confirmed US marketing date.

What source confirms CagriSema’s regulatory status in the European Union?

The European Medicines Agency is the relevant EU source for central marketing authorisation. The supplied trial records do not confirm an EU marketing authorisation for CagriSema.

An EU trial record, press release, or company pipeline entry does not equal an EU marketing authorisation. Check the EMA medicine database for a current regulatory record.

CagriSema side effects, dropouts, and safety limits

The supplied excerpts do not provide complete, arm-level rates for adverse events, serious events, withdrawals, or treatment discontinuation. We therefore do not quote unsupported percentages.

Anyone assessing CagriSema research should review the full trial publication for:

  • Common adverse events
  • Serious adverse events
  • Treatment discontinuations
  • Dose reductions or interruptions
  • Follow-up duration
  • Differences between CagriSema, placebo, and active-control arms
  • The number of participants included in each safety analysis

Did trials find new safety concerns?

Safety conclusions apply only to the populations, doses, and follow-up periods studied. Even when investigators describe findings as consistent with known drug-class profiles, that does not mean every risk is known or that the treatment is suitable for everyone.

How do CagriSema side effects compare with each control arm?

The supplied material does not provide complete arm-level data for a reliable comparison of side effects or discontinuation rates. We cannot state that CagriSema caused more or fewer side effects than each control arm without the full trial tables.

A sound comparison should list the same outcome for every arm. It should separate any adverse event, serious adverse event, treatment-related event, withdrawal because of an adverse event, and study withdrawal.

Why discontinuation rates matter

Average results can look different when participants stop treatment. Stopping the study medicine also differs from leaving a study entirely, because researchers may continue collecting data after treatment ends.

A weight-loss result based only on people who stayed on treatment may differ from a result that counts participants who stopped treatment. Readers should check which analysis the study used.

What safety information is still missing?

The reviewed excerpts do not answer every patient-safety question. They do not provide a complete approved label, full contraindications, final warnings, long-term post-market data, or final instructions for use.

Those details depend on regulatory review. An investigational medicine does not have the same safety information as an approved medicine with a final label.

CagriSema vs semaglutide, Ozempic, and Wegovy

CagriSema contains cagrilintide plus semaglutide. Ozempic and Wegovy contain semaglutide alone and are established products with specific approved labels.

How is CagriSema different from Ozempic?

CagriSema combines two active ingredients and remains investigational in the supplied sources. Ozempic contains semaglutide alone. The products are not interchangeable, and a CagriSema trial result does not change Ozempic’s approved uses.

How is CagriSema different from Wegovy?

Wegovy also contains semaglutide alone, while CagriSema adds cagrilintide. They use different treatment plans and have different regulatory status. A higher percentage from one trial does not prove better results for an individual patient.

Can someone switch from Ozempic or Wegovy to CagriSema?

No general switch plan can be recommended from the reviewed evidence. CagriSema is investigational in the supplied sources. A switch between medicines requires a clinician’s review of the person’s diagnosis, dose, response, side effects, and other medicines.

CagriSema vs tirzepatide, Mounjaro, and Zepbound

CagriSema combines amylin and GLP-1 receptor activity. Tirzepatide, the active ingredient in Mounjaro and Zepbound, targets GIP and GLP-1 receptors.

The cited sources do not include a direct randomized comparison proving that CagriSema is better than either tirzepatide product.

Is CagriSema better than tirzepatide?

The reviewed evidence does not prove that CagriSema is better than tirzepatide. Separate trial percentages cannot establish superiority. A direct randomized comparison would need to use the same population, treatment period, endpoints, dose plans, and analysis method.

Is there evidence for CagriSema after an inadequate response to tirzepatide?

The supplied sources do not establish evidence for CagriSema specifically in people who had an inadequate response to tirzepatide. The CagriSema trials listed here should not be treated as switch studies unless they enrolled and analyzed that group directly.

A person who has not reached a treatment goal on tirzepatide should discuss adherence, dose, side effects, other causes of poor response, and approved alternatives with a clinician.

Why cross-trial weight-loss rankings can mislead

Separate trials may differ in diabetes status, eligibility rules, starting weight, dose escalation, adherence, follow-up, and missing-data methods. Comparing headline percentages cannot replace a direct, randomized trial.

What matters beyond the average percentage

We consider more than average weight change:

  • Side effects and serious warnings
  • Dose tolerance
  • Treatment discontinuation
  • Contraindications
  • Approved indication
  • Long-term maintenance
  • Cost, coverage, and supply
  • The person’s other medicines and health conditions

CagriSema approval, availability, release date, and price

As of October 20, 2026, the supplied sources do not establish an FDA-approved CagriSema label, confirmed US release date, or official US price.

Trial completion, conference presentations, and registry updates are not regulatory approval. We do not turn projected filing or review dates into promised launch dates.

What is the CagriSema launch date?

No confirmed CagriSema launch date is available in the reviewed sources. The United States has no confirmed commercial release date, and the sources do not establish an approved launch in another market.

A launch date can change if a company delays a filing, a regulator requests more data, or an application is not approved. Treat an online date as unconfirmed unless it comes from a current manufacturer announcement or regulatory record.

When will CagriSema be available?

The reviewed material does not confirm when CagriSema will become commercially available in the United States. Clinical-trial access is not the same as routine pharmacy availability.

Availability would require regulatory clearance in the relevant market, a commercial supply, prescribing information, and a lawful distribution channel.

Has CagriSema been approved by the FDA?

FDA approval is not established in the supplied sources as of October 20, 2026. CagriSema trial results do not create an FDA-approved indication.

Check the FDA’s current records for the latest status. Do not treat a social-media post, trial listing, or product advertisement as proof of approval.

Will CagriSema be covered by insurance?

No coverage policy for CagriSema can be confirmed while the product lacks an established approved label and commercial launch in the reviewed sources. Insurance coverage would depend on regulatory approval, the final label, the insurer’s policy, and the patient’s plan.

An insurer’s coverage of Ozempic, Wegovy, Mounjaro, or Zepbound does not mean it will cover CagriSema. Coverage decisions for an investigational product are separate.

Does CagriSema have a confirmed price?

No confirmed US price appears in the supplied sources. Trial findings cannot predict list price, insurance coverage, discounts, cash cost, or supply. Even after launch, list price and patient cost may differ.

Can you buy CagriSema online now?

The reviewed sources do not establish a commercially available, FDA-approved CagriSema product. A website or vial using the name cannot verify its ingredients, strength, purity, sterility, storage, or manufacturer.

How to check a CagriSema claim on Reddit or social media

Trace the claim to an original clinical-trial record, peer-reviewed paper, regulatory record, or manufacturer document. Check the population, dose, study length, analysis method, and publication date rather than relying on screenshots.

A claim that CagriSema has “launched” should also identify the country, regulator, approval date, product label, manufacturer, and lawful pharmacy source.

Why separate ingredient access is not the same product

Combining semaglutide with a substance marketed as cagrilintide does not recreate the studied product. Formulation, dose ratio, manufacturing controls, and storage all matter.

Patients considering compounded medicine can read our guide to checks for a compounded semaglutide vial. It does not validate products sold as CagriSema.

What patients can do while CagriSema remains investigational

We recommend discussing currently available options with a licensed clinician rather than waiting for an unconfirmed launch. A review should cover medical history, current medicines, treatment goals, contraindications, previous side effects, cost, and supply.

Through Temi’s medication platform, patients can complete an online intake, meet with a clinician where available, and manage eligible prescriptions and follow-up care. We do not prescribe investigational CagriSema outside a lawful clinical trial.

What to bring to a weight-loss care visit

Bring a list of prescriptions, supplements, allergies, diagnoses, previous weight-management treatments, recent laboratory results, and relevant insurance information. Patients needing help with an existing prescription can use our prescription refill support.

When to seek urgent medical care

Seek urgent assessment for severe or persistent symptoms, an allergic reaction, intense abdominal pain, repeated vomiting, fainting, or any emergency symptoms identified by a clinician. Less severe side effects should still be discussed during follow-up.

CagriSema questions, answered

Is CagriSema a form of semaglutide?

It contains semaglutide, but also includes cagrilintide. It is not interchangeable with a semaglutide-only product.

Is CagriSema better than Mounjaro or Zepbound?

The reviewed sources contain no direct randomized evidence proving that it is better.

When will CagriSema be available in the United States?

The supplied sources do not establish a confirmed US release date as of October 20, 2026.

What were the main CagriSema trial results?

The ADA reported weight loss of up to 22.7% in studied adults without diabetes and 15.7% in those with type 2 diabetes. These are population-specific findings, not individual forecasts.

Has CagriSema been submitted to the FDA?

The reviewed sources do not establish a confirmed FDA submission or publicly verified application number. Check current FDA records and manufacturer statements for an update.

Will insurance cover CagriSema?

No coverage can be confirmed from the reviewed sources. Insurance coverage would depend on approval, commercial availability, the final label, and the patient’s plan.

What device will CagriSema use?

The trials used a once-weekly injection. The final commercial device has not been confirmed in the reviewed material.

FAQ

Is CagriSema FDA approved?

FDA approval is not established in the supplied sources. Patients should verify current status through official regulatory records.

Is CagriSema the same as Ozempic?

No. CagriSema combines cagrilintide and semaglutide; Ozempic contains semaglutide alone.

Is CagriSema better than Mounjaro?

No direct comparison in the reviewed evidence proves that claim. Cross-trial percentages are not enough.

Can I purchase CagriSema online?

The sources do not establish an approved commercial product. We recommend avoiding products whose ingredients, manufacturer, sterility, and regulatory status cannot be verified.

Does CagriSema have a launch date?

No confirmed US launch date appears in the reviewed sources as of October 20, 2026.

Is there evidence for CagriSema after tirzepatide does not work?

The supplied sources do not establish evidence for that specific switch group. The listed CagriSema trials should not be treated as studies of people who had an inadequate response to tirzepatide.

Review approved treatment options now

Use Temi to request a clinician review of approved treatment options, current prescriptions, side effects, refill needs, and costs. Eligibility depends on an individual medical assessment.

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.